Ascendis Pharma beat Q4 earnings and revenue estimates, driven by a $100M Novo Nordisk deal and Yorvipath's EU launch.

Fintel reports that on February 13, 2025, UBS upgraded their outlook for AstraZeneca PLC - Depositary Receipt () ...

UBS upgraded AstraZeneca from 'neutral' to 'buy' on Thursday, citing the pharmaceutical firm's "sector-leading" drug pipeline ...

UBS has upgraded AstraZeneca to a ‘buy’, citing the London-listed pharmaceutical firm’s "sector-leading" drug pipeline.

Barclays analyst Duffy Fischer upgraded DuPont de Nemours, Inc. DD from Underweight to Equal-Weight and boosted the price ...

UBS upgraded AstraZeneca (AZN) to Buy from Neutral with a price target of 14,200 GBp, up from 11,500 GBp. The firm cites the company’s ...

UBS raises AstraZeneca to 'buy' (neutral) - price target 14,200 (11,500) pence JPMorgan cuts Smiths Group price target to 2,420 (2,440) pence - 'overweight' ...

Stephens Inc. AR lessened its position in shares of AstraZeneca PLC (NASDAQ:AZN – Free Report) by 5.2% in the fourth quarter, Holdings Channel reports. The fund owned 24,987 shares of the company’s ...

AstraZeneca (NASDAQ:AZN) stock received a positive assessment from UBS, as analyst Matthew Weston upgraded the pharmaceutical giant's rating from Neutral to Buy. The upgrade was accompanied by a ...

In a report released today, Matthew Weston from UBS upgraded AstraZeneca (AZN – Research Report) to a Buy, with a price target of £142.00. The ...